FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Textron Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We increase our 12-month target price by $4 to $111, or 14.5x our 2027 EPS estimate, above TXT's three-year average forward P/E of 13.2x but still well below peers' average forward P/E of 25.1x. We raise our 2026 EPS estimate by $0.03 to $6.68 and keep 2027E at $7.65. TXT's announcement to separate its Industrial segment (~$3.2B revenue) to become a pure-play aerospace and defense company is transformational. New Textron will have ~$12B in revenue with 100% A&D exposure, anchored by leading positions in business aviation (Textron Aviation), military/commercial rotorcraft (Bell), and defense systems. The $19.2B backlog provides multi-year revenue visibility, with Aviation's $8B backlog up 4x from pre-Covid levels. The MV-75 Cheyenne program represents a significant growth driver as it transitions from development to production, supported by strong DoD funding commitments. We view the separation as strategically sound, enabling enhanced focus, improved margins (expanding 120 bps), and accelerated growth (150 bps higher).

Related Articles

Mining & Metals

Earnings Flash (KBL.TO) K-Bro Linen Reports Q1 Revenue $139.1M, Up 52.9% YoY

$KBL.TO
Equities

Occidental Petroleum Q1 Adjusted Earnings Rise, Revenue Falls

Occidental Petroleum (OXY) reported Q1 adjusted earnings late Tuesday of $1.06 per diluted share, up from $0.87 a year earlier.Analysts polled by FactSet expected $0.60.Revenue for the three months ended March 31 was $5.23 billion, down from $5.70 billion a year earlier.Analysts surveyed by FactSet expected $5.44 billion.

$OXY
Mining & Metals

Curaleaf Swings to Q1 Profit As Revenues Beat Expectations

Curaleaf (CURA.TO) reported a swing to a surprise first-quarter profit, boosted by better than expected revenues.The company reported net income from continuing operations of US$70.1 million, or US$0.09 per share, compared with a loss of US$50.1 million, or a loss of US$0.09 per share. Analysts polled by FactSet had forecast a loss of US$0.08 per share.Revenue climbed 6% over the same period, to US$324 million, beating the US$317 million forecast."The macro headwinds that constrained growth over the past three years are now beginning to turn into meaningful tailwinds. Moreover, the historic rescheduling of medical cannabis provides a shift in the trajectory of our business and the industry overall, for which we are well-positioned," said chief executive Boris Jordan. "The investments we've made in the core pillars of our "Built for Growth" strategy are translating directly into tangible performance," he added.Curaleaf shares closed up $0.28, to $4.73 on Tuesday on the Toronto Stock Exchange.

$CURA.TO$HMMJ.TO